This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pedrinelli, R. Articles by Mariani, M. Search for Related Content PubMed PubMed Citation Articles by Pedrinelli, R. Articles by Mariani, M. Pubmed/NCBI databases Medline Plus Health Information High Blood Pressure Related Collections Other hypertension

(Hypertension. 2000;35:48.)
© 2000 American Heart Association, Inc.

Scientific Contributions

Microalbuminuria and Pulse Pressure in Hypertensive and Atherosclerotic Men

Roberto Pedrinelli; Giulia Dell’Omo; Giuseppe Penno; Simona Bandinelli; Alessio Bertini; Vitantonio Di Bello; Mario Mariani

From Dipartimento Cardiotoracico (R.P., G.D., M.M.), Malattie del Metabolismo (G.P., S.B.), Medicina Interna (A.B., V.D.B.), Università di Pisa, Pisa, Italy.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—To identify the biological covariates of microalbuminuria (albuminuria 15 µg/min) in nondiabetic subjects, brachial blood pressure, echocardiographic left ventricular mass, and other cardiovascular and metabolic parameters were evaluated in 211 untreated males (38 normal controls, 109 uncomplicated stage 1 to 3 essential hypertensives, and 64 patients with clinically stable atherosclerotic peripheral vascular disease either with [n=44] or without [n=20] essential hypertension) with normal cardiac and renal function. Compared with normoalbuminuric subjects, microalbuminuric subjects (n=67) were characterized by higher systolic blood pressure, comparable diastolic blood pressure, and, therefore, wider pulse pressure. Greater prevalence of hypertension, peripheral vascular disease, left ventricular hypertrophy, and reduced HDL cholesterol values further distinguished microalbuminuric from normoalbuminuric subjects in univariate comparisons. The risk of microalbuminuria increased by ascending pulse pressure quintiles in age-corrected logistic regression models, in which pulse pressure was more predictive than systolic pressure and was independent of mean pressure. When microalbuminuric status was regressed against a series of dichotomous (vascular and active smoker status) and continuous (age, pulse and mean pressure, left ventricular mass index, and HDL and LDL cholesterol) variables, only pulse pressure, left ventricular mass index, and smoking status were independent predictors. The association of increased albuminuria with wider pulse pressure, a correlate of the pulsatile hemodynamic load and conduit vessel stiffness as well as an important cardiovascular risk factor, may explain why microalbuminuria predicts cardiovascular events in nondiabetic subjects. The independence from concomitant vascular disease also suggests that wider pulse pressure, rather than representing a simple marker for atherosclerotic disease, influences albuminuria directly.

Key Words: albuminuria • pressure • hypertension, essential • vascular diseases • mass, ventricular

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Microalbuminuria (ie, an abnormal urinary albumin excretion [UAE] in a range not detectable by the usual dipstick methods for urine protein) is associated with an increased cardiovascular risk in hypertensive patients^1,2 and nondiabetic populations.^{3 4 5} Yet, why a renal parameter of glomerular origin behaves as a marker of atherosclerotic cardiovascular disease remains obscure, and the biological factors influencing UAE still await some deeper clarification.

To specify to a better extent the biological covariates of microalbuminuria in nondiabetic subjects, we have evaluated cross-sectionally a series of cardiovascular and metabolic parameters in a large group of normal control subjects, subjects with essential hypertension (EH), and patients with atherosclerotic vascular disease.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Subjects
The study was carried out on 211 eligible sedentary subjects referred to our unit from 1996 to 1998 for screening and treatment of hypertension and related cardiovascular risk factors. Inclusion criteria required male gender, negative urine dipstick test, normal urinary sediment and renal ultrasound, plasma glucose <7.8 mmol/L (120 mg/dL), serum creatinine <110 µmol/L (1.4 mg/dL), total serum cholesterol <7.8 mmol/L (300 mg/dL), body mass index (BMI) <27 kg/m², and preserved systolic cardiac function (ejection fraction >50%) (see Table 1 for the overall demographic and clinical characteristics). One hundred nine patients had stage 1 to 3 uncomplicated EH, 20 had atherosclerotic peripheral vascular disease (PVD), and 44 were affected by both conditions (EH/PVD). Thirty-eight normal subjects were the controls.

View this table: [in this window] [in a new window]   Table 1. Demographics and Clinical Characteristics of the 211 Subjects of the Sample

Clinical screenings were based on history, physical examination, routine tests, and neck and lower limb color-echo Doppler sonography in most subjects. All parameters reported in the present study were collected in a 2-week period.

Diagnosis of hypertension was based on casual blood pressure (BP) values >140/90 mm Hg and/or antihypertensive treatment at the first contact, and secondary forms of hypertension were excluded by routine examinations, including renal color-echo Doppler sonography and, if needed, angiography. If patients had received treatment, antihypertensive drugs were withdrawn 4 weeks before the study; no patient had ever been on lipid-lowering drugs. PVD was diagnosed by intermittent claudication (pain-free walking distance >200 m on a treadmill) confirmed by ankle-brachial pressure measurements <0.9 at one or both sides. According to institutional guidelines, subjects were aware of the investigational nature of the study and agreed to participate. The study was carried out in accordance with the Declaration of Helsinki, and the protocol was approved by the local Ethical Committee.

Experimental Procedures
UAE was measured by nephelometry (Behring; limit of detection 0.1 mg/dL, interassay variation coefficient 3.5%) on samples collected from 8:00 PM to 8:00 AM during 3 consecutive days. Sitting BP was measured in the early afternoon by an automated oscillometric device (SpaceLabs 90207) throughout a 2-hour period. Wall thickness and chamber diameters were determined at or just below the mitral valve tips, by the leading edge–to–leading edge method on monodimensional and bidimensional echocardiograms (Hewlett Packard Sonos 1000, with 2.5- and 3.5-MHz transducers) according to recommendations of the American Society of Echocardiography. Clinically significant aortic insufficiency was excluded in all subjects by Doppler examinations. Anthropometric measurements (height and weight) were made after each participant had removed his shoes and upper garments. Blood samples were obtained between 8:00 and 9:00 AM after an overnight fasting and 15 minutes of supine rest. Total cholesterol, HDL cholesterol, and triglycerides were assessed by enzymatic colorimetric techniques (Boehringer-Mannheim). Serum and urine creatinine levels were assayed by standard colorimetric methods.

Data Processing
UAE (µg/min) was the median of 3 consecutive overnight collections (median variation coefficient 25%). Microalbuminuria was defined as any UAE value 15 µg/min⁶ in the presence of a negative dipstick test for urine protein. Systolic BP (SBP) and diastolic BP (DBP) values were the mean of at least 10 recordings taken over a 2-hour period. Pulse pressure (PP) was the arithmetic difference between averaged SBP and DBP values. Mean BP (MBP) was DBP +1/3 PP. BMI (body weight/squared surface area), creatinine clearance, and LDL cholesterol [total cholesterol-(HDL cholesterol+triglyceride/5)] were calculated from standard formulas. Smoking status was defined as active smokers versus nonsmokers, without distinction between former smokers and those who have never smoked.

Left ventricular mass (Penn convention) was corrected for height to derive the left ventricular mass index (LVMI, g/m). Myocardial hypertrophy was defined as LVMI 143 g/m, a partition value associated with all-cause mortality and sudden death in population-based investigations.^{7 8} Stroke volume (SV) was the difference between end-diastolic and end-systolic left ventricular volume.

Statistics
The association of microalbuminuria (coded as follows: 0, normoalbuminuria; 1, microalbuminuria) with continuous and categorical (including quintiles of PP) covariates was analyzed by logistic regression (maximum likelihood method) using a backward stepwise procedure (probability to remove, P<0.05) to identify the independent regressors. Odds ratios (ORs, ie, the exponentiated regression coefficients) were used to estimate relative risks and 95% CIs. Intraindividual association of continuous variables was evaluated by nonparametric Spearman rank correlation coefficients. Differences among continuous variables were tested by ANOVA covariated for age, and a multiple range test was used to evaluate differences among means. Categorical parameters were tested by Cochran-Armitage exact tests.

Data were reported as mean±1 SD or median and range in the presence of skewed data. Statistical significance was set at P<0.05 unless otherwise indicated.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Clinical Characteristics by Microalbuminuric Status
Older age, higher SBP, comparable DBP, wider PP with the same SV, greater prevalence of hypertension, atherosclerotic PVD, cardiac hypertrophy, higher LVMI and MBP, and lower HDL cholesterol values distinguished microalbuminuric subjects (median UAE 28 [range 15 to 271] µg/min, n=67) from normoalbuminuric subjects (median UAE 7 [range 2 to 14] µg/min, n=144) (Table 2). Differences in smoking status and LDL cholesterol were of borderline (P<0.1) significance.

View this table: [in this window] [in a new window]   Table 2. Age-Corrected Comparisons of Cardiovascular, Renal, and Metabolic Parameters in Subjects With and Without Microalbuminuria

Clinical Characteristics by Vascular Status
Irrespective of BP, subjects with arteriopathy were older and had a more atherogenic lipid profile. Clinical characteristics of the study subjects are shown in Table 3.

View this table: [in this window] [in a new window]   Table 3. Cardiovascular, Renal, and Metabolic Parameters According to Vascular Status (EH, PVD, and EH/PVD)

Compared with patients with EH, patients with EH/PVD showed a greater frequency of microalbuminuria, higher UAE and SBP, lower DBP, wider PP, and similar MBP.

Cardiovascular parameters did not differ between normotensive PVD patients and controls.

Intraindividual Correlations
Age-related influences were most evident on creatinine clearance (inversely, r=-0.44, P<0.001), PP (r=0.40, P<0.001), and, in decreasing order, SBP (r=0.23, P<0.001), UAE (r=0.20, P<0.004), and LVMI (r=0.18, P<0.01). Lipids and DBP were independent of age.

UAE was correlated with PP (Figure 1), SBP (r=0.38 for both, P<0.001), MBP (r=0.28, P<0.001), and, to a lower extent, DBP (r=0.18, P<0.02). Other statistically significant covariates of albuminuria were LVMI (r=0.21, P<0.01), total cholesterol (r=0.14, P<0.05), LDL cholesterol (r=0.21, P<0.01), and HDL cholesterol (inversely, r=-0.22, P<0.01).

View larger version (18K): [in this window] [in a new window]   Figure 1. Plot of UAE (log scale) vs PP. The rank correlation coefficient was 0.38 (P<0.001, n=211).

PP was closely correlated with SBP (r=0.75, P<0.001) and MBP (r=0.43, P<0.001) but not DBP (r=0.10). Systolic and diastolic values were also correlated (r=0.69, P<0.001). The rank correlation of PP and SBP with LVMI was 0.17 (P<0.01) and 0.33 (P<0.001), respectively.

Risk of Microalbuminuria by PP Quintiles
The proportion of subjects with microalbuminuria (Figure 2, left panel; P<0.001) and their UAE levels (Figure 2, right panel; P<0.007) increased by increasing PP quintiles (cutoff points 45, 50, 59, and 68 mm Hg; n=40, 39, 46, 43, and 43).

View larger version (15K): [in this window] [in a new window]   Figure 2. Percentage of patients with microalbuminuria (left) and UAE values (right) by PP quintiles (cutoff points 45, 50, 59, and 68 mm Hg; n=40, 39, 46, 43, 43). To provide adequate information about the skewed UAE distribution, results are presented as box-and-whisker plots. The central box encloses the middle 50% of the data, the horizontal line inside the box represents the median, and the mean is plotted as a cross. Vertical lines (whiskers) extend from each end of the box and cover 4 interquartile ranges. Points indicate outliers.

The age-corrected risk of microalbuminuria did not differ from 1 in the intermediate PP quintiles and increased by 3.4-fold (95% CI 1.24 to 9.3, P<0.03) and 5.3-fold (95% CI 1.9 to 15, P<0.003) in the fourth and fifth quintile, respectively (Figure 3). The trend did not change when PVD patients were excluded from the analysis (cutoff points 44, 50, 54, and 60 mm Hg; n=29, 28, 30, 30, and 30; OR of the upper quintile versus baseline 5.8; 95% CI 1.41 to 24; P<0.02, n=147).

View larger version (40K): [in this window] [in a new window]   Figure 3. Age-corrected risk of microalbuminuria by PP quintiles. Ninety-five percent CIs are reported at the top of each histogram (n=211). For statistics, see text.

Pulsatile and Steady BP Components and Risk of Microalbuminuria
The relative importance of PP, SBP, DBP, and MBP in predicting microalbuminuria was addressed in logistic regression models, including BP parameters alone and in combination. Because age was an univariate predictor of microalbuminuria risk (OR 1.39/10 years, 95% CI 1.05 to 1.56, P<0.01), all analyses included age as a covariate.

PP, as such, was associated (P<0.001) with a 62% increase in risk for every 10 mm Hg rise (95% CI 1.35 to 1.9) compared with a 41% increase for every 10 mm Hg rise in SBP (95% CI 1.22 to 1.59, P<0.001). When PP and SBP were combined, PP remained a significant (P<0.03) predictor of microalbuminuria (OR/10 mm Hg increase 1.43, 95% CI 1.03 to 1.83), and SBP did not (OR/10 mm Hg increase 1.17, 95% CI 0.99 to 1.45, P<0.2). The risk associated with PP (OR/10 mm Hg increase 1.55, 95% CI 1.26 to 1.85, P<0.001) was independent of MBP (OR/10 mm Hg increase 1.17, 95% CI 0.99 to 1.5, P<0.2); when evaluating SBP and DBP in the same model, higher SBP (OR/10 mm Hg increase 1.61, 95% CI 1.34 to 1.89, P<0.001) and lower DBP (OR/10 mm Hg decrease 0.096, 95% CI 0.092 to 0.099, P<0.03) predicted microalbuminuria.

Multivariate Components of the Risk of Microalbuminuria
Among the dichotomous (vascular and active smoker status) and continuous (age, PP, MBP, LVMI, and HDL and LDL cholesterol) variables that distinguished (P<0.1) microalbuminuric from normoalbuminuric subjects in one-to-one comparisons, only PP (OR/10 mm Hg rise 1.6, 95% CI 1.3 to 1.9, P<0.001), LVMI (OR/10 g/m 1.14, 95% CI 1.03 to 1.25, P<0.02), and smoking (OR 1.97, 95% CI 1.001 to 3.98, P=0.05) predicted microalbuminuria independently (Figure 4). The overall percentage of deviance explained by the model was 18%.

View larger version (34K): [in this window] [in a new window]   Figure 4. Risk of microalbuminuria by increasing PP, LVMI, and smoking status according to a multivariate logistic model [(Exp- 6.28+0.058xPP+0.014xLVMI+0.68xsmoking status/1+Exp-6.28+0.058xPP+0.014xLVMI+0.68xsmoking status)x100]. For statistics, see text. The 12% risk of microalbuminuria of a nonsmoker male (PP 50 mm Hg, LVMI 100 g/m) contrasts with the 65% risk of an active smoker male (PP 70 mm Hg, LVMI 150 g/m).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The original finding of this cross-sectional evaluation of the biological covariates of microalbuminuria in a large and carefully screened group of nondiabetic males was the independent predicting power of a wider PP, a readily obtainable measure of pulsatile flow,^{9 10} in contrast with the lack of statistical weight of MBP, a surrogate measure of steady flow,^{9 10} examined simultaneously with PP. The risk profile associated with progressive PP widening did not differ from 1 in the intermediate range of values and increased sharply only at 60 mm Hg. A nonlinear trend implies that a threshold exists above which the renal impact of that hemodynamic factor becomes more evident and, reciprocally, that its influence may be obscured by other biological mechanisms at lower PP levels. PP also provided information additional to SBP, in spite of the strict collinearity between the 2 parameters. Risk of microalbuminuria was predicted by both lower DBP and higher SBP entered in the same logistic regression model, indicating that PP compounded the exaggerated rises in the latter and the less than proportional increments or actual decrements in the former. Determinants of PP include SV, rate of systolic ejection, and stiffness of the arterial tree.^{9 10} Because SV measurements did not vary across the spectrum of UAE values, increased arterial stiffness was a more likely cause of the wider PP in our microalbuminuric subjects, probably because of arteriosclerotic degeneration of the major capacitance arteries, although other mechanisms cannot be ruled out on the basis of our data.¹¹

An obvious question regards confounders, primarily atherosclerosis, a disease in which segmental macrovascular lesions and diffuse microvascular abnormalities tend to coexist,¹² affecting about one third of the components of our sample. Atherosclerosis may also increase UAE by damaging diffusely vascular endothelium,¹³ but our finding of a normal UAE in the group of normotensive patients with a fully developed arterial lower limb disease, in itself a harbinger of widespread macroangiopathy,¹⁴ does not support that prediction. It was only in the presence of an exaggerated PP, a likely result of the stiffening of large arteries through collagen neoformation and excess calcium deposition at the affected sites,^{11 15} that the prevalence of microalbuminuria increased strikingly. Our data, therefore, suggest an only indirect relation between atherosclerotic macroangiopathy and renal microvascular changes, with elevated BP, particularly its pulsatile elements, acting as the chain in the link; however, our data do confirm that subclinical kidney damage is frequent in EH that is complicated by PVD.^{3 16} The increasing prevalence of microalbuminuria by ascending PP quintiles in uncomplicated subjects analyzed separately from atherosclerotic patients and the overall results of the multivariate logistic regression analyses further discount a direct link between advanced atherosclerosis and albuminuria, in agreement with data from our¹⁷ and other¹⁸ laboratories. This negative conclusion contrasts with the inferences drawn from the results of previous cross-sectional observations of patients with atherosclerotic PVD,³ perhaps because uninterrupted antihypertensive treatment may have obscured pressure-related effects in that later study. Age-related confounding could also be hypothesized because, as expected,¹⁹ PP and, to a lesser extent, even UAE showed age-related changes, but demographic differences between normoalbuminuric and microalbuminuric subjects were not huge, and, besides, statistics accounted for this factor. Cardiovascular risk factors such as dyslipidemia, diabetes, and smoking may influence both UAE²⁰ and conduit vessel distensibility,¹⁰ but total and LDL cholesterol values were evenly distributed, and HDL cholesterol, albeit reduced in the present and in a previous study²⁰ of microalbuminuric subjects, did not emerge as a critical factor in the statistical analyses. Furthermore, diabetics were excluded from the trial, and the albuminuric action of smoking, already shown in past studies^{21 22} and confirmed in the present study, was additive to that of PP. Thus, the strength of statistical association, its persistence after adjusting for potential confounders, and inferential reasoning make plausible a direct connection between microalbuminuria and elevated PP. Similar results were obtained in the studies that examined the behavior of PP^{23 24} and, more frequently, SBP (a measure of vascular compliance²⁵ and a variable strictly related to PP) as determinants of albuminuria in unselected populations^26,27 and hypertensive patients.^22,28 Regarding mechanisms, an excessive pulsatile load altered gluteal arteriolar structure,²⁹ and the same may happen at the renal level, where wall hypertrophy characterized the nephrosclerotic biopsies harvested from mildly proteinuric EH patients.³⁰ In light of the recent demonstration of the relation between microalbuminuria and future development of renal insufficiency in EH,² it may be relevant, in this context, to consider the independent association between increasing serum creatinine and faster pulse-wave velocity, a measure of arterial stiffness, in EH patients.³¹ SBP also frequently overcame DBP as a predictor of overt kidney damage and end-stage renal disease,³² a clinical condition in which arterial stiffness is almost universal.³³ Cross-sectional associations are to be taken with caution, though, and we are aware that our present cross-sectional findings might be compatible with exactly opposite interpretations, eg, an effect of urine albumin on PP. Prospective follow-ups of populations (less selected than ours and mainly composed of subjects referred to a tertiary diagnostic center) will be needed to evaluate in further detail any role of the pulsatile BP components on the kidney. The discrepancy between overnight measurement of urine and early afternoon BP recordings or gender-related phenomena in our all-male group should also be considered. Technical limits may also exist in that peripheral and central PPs differ to a variable extent,⁹ which is not a critical point, though, in view of the fact that differences in hemodynamic regimens are attenuated in middle-aged sedentary subjects.⁹

Because brachial PP determination predicts morbid events in prospective cohorts of essential hypertensive subjects,^{34 35} our data may help to understand better why microalbuminuria behaves as a marker of cardiovascular risk in nondiabetic hypertensive subjects. Moreover, the association with other primary risk factors, such as increased LVMI and left ventricular hypertrophy, decreased HDL cholesterol levels, and tobacco smoking, legitimately qualifies microalbuminuria as an integrated marker of cardiovascular risk. The list of damaging factors associated with the presence of microalbuminuria may, however, be incomplete; as a matter of fact, additional mechanisms are likely (eg, see References 21 and 36^{21 36} ), in view of the fact that our logistic model left 80% of the total microalbuminuria deviance unexplained. Furthermore, our cardiac mass data confirm the correlation with UAE,³⁷ an association usually interpreted as a reflection of the prevailing pressor load on the kidney and the heart. Quite unexpectedly, however, the statistical link between the 2 parameters was independent of pressure, a result also recently reported by Gatzka et al.³⁸ The data might perhaps be explained by circulating factors that are produced in greater amount by a hypertrophic heart³⁹ and by an increasing renal permeability to albumin.⁴⁰ This interesting possibility requires further evaluation in future studies.

In conclusion, the association of increased albuminuria with wider PP, a correlate of the pulsatile hemodynamic load and conduit vessel stiffness, which is in itself an important cardiovascular risk factor, and left ventricular hypertrophy may help to explain why microalbuminuria predicts cardiovascular events in nondiabetic subjects. The independence from concomitant vascular disease also suggests that wider PP, rather than representing a simple marker for atherosclerotic disease, influences albuminuria directly.

	Footnotes

 
Reprint requests to Roberto Pedrinelli, MD, Dipartimento Cardiotoracico, Università di Pisa, 56100 Pisa, Italy.

Received July 1, 1999; first decision July 16, 1999; accepted August 18, 1999.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, Clausen P, Appleyard M, Jensen G. Microalbuminuria and its relation to cardiovascular disease and risk factors: a population-based study of 1254 hypertensive individuals. J Hum Hypertens. 1997;11:727–732.[Medline] [Order article via Infotrieve]
2. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens. 1998;16:1325–1333.[Medline] [Order article via Infotrieve]
3. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non diabetic subjects. Lancet. 1988;ii:530–533.
4. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation. 1995;91:831–837.[Abstract/Free Full Text]
5. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as a predictor of increased mortality in elderly people. BMJ. 1990;300:297–300.
6. Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, Jensen G. Urinary albumin excretion in a population based sample of 1011 middle aged non diabetic subjects: the Copenhagen City Heart Study Group. Scand J Clin Lab Invest. 1993;53:867–872.[Medline] [Order article via Infotrieve]
7. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart study. N Engl J Med. 1990;322:1561–1566.[Abstract]
8. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk of sudden death. J Am Coll Cardiol. 1998;32:1454–1459.[Abstract/Free Full Text]
9. Smulyan H, Safar ME. Systolic blood pressure revisited. J Am Coll Cardiol. 1997;29:1407–1413.[Abstract]
10. Glasser SP, Arnett DK, McVeigh GE, Finkelstein SM, Bank AJ, Morgan DJ, Cohn JN. Vascular compliance and cardiovascular disease: a risk factor or a marker? Am J Hypertens.. 1997;10:1175–1189.[Medline] [Order article via Infotrieve]
11. Benetos A, Laurent S, Asmar RG, Lacolley P. Large artery stiffness in hypertension. J Hypertens. 1997;15(suppl 2):S89–S97.
12. Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Delagrange D, Creager MA, Selwin AP, Ganz P. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol. 1995;75:71b–74b.
13. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia. 1989;32:219–226.[Medline] [Order article via Infotrieve]
14. Criqui MH, Denenberg JO. The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med. 1998;3:241–245.[Abstract/Free Full Text]
15. Safar ME, Toto-Moukomo JJ, Bouthier JA, Asmar RA, Laurent SM. Increased pulse pressure in patients with arteriosclerosis obliterans of the lower limbs. Arteriosclerosis. 1987;7:232–237.[Abstract/Free Full Text]
16. Fabsitz RR, Sidaway AN, Go O, Lee ET, Weity TK, Devereux RB, Howard BV. Prevalence of peripheral arterial disease and associated risk factors in American Indians. Am J Epidemiol. 1999;149:330–338.[Abstract/Free Full Text]
17. Pedrinelli R, Penno G, Dell’Omo G, Bandinelli S, Giorgi D, Di Bello V, Nannipieri M, Navalesi R, Mariani M. Transvascular and urinary leakage of albumin in atherosclerotic and hypertensive men. Hypertension. 1998;32:312–318.
18. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, Bouter LM, Stehouwer CDA. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol. 1999;19:617–624.[Abstract/Free Full Text]
19. Franklin SS, Gustin W, Wong ND, Larson MGF, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure: the Framingham Heart Study. Circulation. 1997;96:308–315.[Abstract/Free Full Text]
20. Campese VM, Bianchi S, Bigazzi R. Association between hyperlipidemia and microalbuminuria in essential hypertension. Kidney Int. 1999;56(suppl 71):S10–S13.
21. Pedrinelli R, Giampietro O, Carmassi O, Melillo E, Dell’Omo G, Catapano G, Matteucci E, Talarico L, Morale M, De Negri F, Di Bello V. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 1994;344:14–18.[Medline] [Order article via Infotrieve]
22. Mimran A, Ribstein J, Du Cailar G, Halimi JM. Albuminuria in normals and essential hypertension. J Diabetes Complications. 1994;8:150–156.[Medline] [Order article via Infotrieve]
23. Clausen P, Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Ambulatory blood pressure and urinary albumin excretion in clinically healthy subjects. Hypertension. 1998;32:71–77.[Abstract/Free Full Text]
24. Kasiske BL, Rith-Najarian S, Casper ML, Croft JB. American Indian heritage and risk factors for renal injury. Kidney Int. 1998;54:1305–1310.[Medline] [Order article via Infotrieve]
25. Safar ME, St Laurent S, Safavian AL, Pannier BM, London GM. Pulse pressure in sustained essential hypertension: a haemodynamic study. J Hypertens. 1987;5:213–218.[Medline] [Order article via Infotrieve]
26. Cirillo M, Senigalliesi L, Laurenzi M, Alfieri R, Stamler J, Stamler R, Panarelli W, De Santo NG. Microalbuminuria in non diabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels and smoking: the Gubbio population study. Arch Int Med. 1998;158:1933–1939.[Abstract/Free Full Text]
27. Goetz FC, Jacobs DR, Chavers B, Roel J, Yelle M, Sprafka JM. Risk factors for kidney damage in the adult population of Wadena, Minnesota: a prospective study. Am J Epidemiol. 1997;145:91–102.[Abstract/Free Full Text]
28. Agewall S, Fagerberg B. Risk factors that predict development of microalbuminuria in treated hypertensive men: the Risk Intervention Study Group. Angiology. 1996;47:963–972.
29. James MA, Watt PAC, Potter JF, Thurston H, Swales JD. Pulse pressure and resistance artery structure in the elderly. Hypertension. 1995;26:301–306.[Abstract/Free Full Text]
30. Fogo A, Breyer JA, Smith MC, Cleveland WH, Agodoa L, Kirk KA, Glassock R. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) trial. Kidney Int. 1997;51:244–252.[Medline] [Order article via Infotrieve]
31. Blacher J, Asmar R, Saliha D, London GM, Safar ME. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension. 1999;33:1111–1117.[Abstract/Free Full Text]
32. Whelton PK, Perneger TV, He J, Klag MJ. The role of blood pressure as a risk factor for renal disease: a review of the epidemiologic evidence. J Hum Hypertens. 1996;10:683–689.[Medline] [Order article via Infotrieve]
33. London GM, Drueke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int. 1997;51:1678–1995.[Medline] [Order article via Infotrieve]
34. Benetos A, Rudnichi A, Safar M, Guize L. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension. 1998;32:560–564.[Abstract/Free Full Text]
35. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Pede S, Porcellati C. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension. 1998;32:983–988.[Abstract/Free Full Text]
36. Hoogeveen EK, Kostense PJ, Jager A, Heine RJ, Jakobs C, Bouter LM, Donker AJM, Stehouwer CDA. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int. 1998;54:203–209.[Medline] [Order article via Infotrieve]
37. Pedrinelli R, Di Bello VA, Catapano G, Talarico L, Materazzi F, Santoro G, Giusti C, Mosca F, Melillo E, Ferrari M. Microalbuminuria is a marker of left ventricular hypertrophy but not hyperinsulinemia in non diabetic atherosclerotic patients. Arterioscler Thromb. 1993;13:900–906.[Abstract/Free Full Text]
38. Gatzka CD, Reid CM, Lux A, Dart AM, Jennings G. Left ventricular mass and microalbuminuria: relation to ambulatory blood pressure: Hypertension Diagnostic Service Investigators. Clin Exp Pharmacol Physiol. 1999;26:514–516.[Medline] [Order article via Infotrieve]
39. Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y, Kangawa K, Matsuo H, Omae T, Matsuoka H. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension. 1996;28:22–30.[Abstract/Free Full Text]
40. Mc Murray J, Seidelin PH, Howey JE, Balfour DJ, Struthers AD. The effect of atrial natriuretic factor on urinary albumin and beta 2-microglobulin excretion in man. J Hypertens. 1988;6:783–786.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				D. D. Schocken, E. J. Benjamin, G. C. Fonarow, H. M. Krumholz, D. Levy, G. A. Mensah, J. Narula, E. S. Shor, J. B. Young, and Y. Hong Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group Circulation, May 13, 2008; 117(19): 2544 - 2565. [Abstract] [Full Text] [PDF]

				N. K. Sweitzer, M. Shenoy, J. H. Stein, S. Keles, M. Palta, T. LeCaire, and G. F. Mitchell Increases in Central Aortic Impedance Precede Alterations in Arterial Stiffness Measures in Type 1 Diabetes Diabetes Care, November 1, 2007; 30(11): 2886 - 2891. [Abstract] [Full Text] [PDF]

				J. W. Newman, G. A. Kaysen, B. D. Hammock, and G. C. Shearer Proteinuria increases oxylipid concentrations in VLDL and HDL but not LDL particles in the rat J. Lipid Res., August 1, 2007; 48(8): 1792 - 1800. [Abstract] [Full Text] [PDF]

				A. Tsakiris, M. Doumas, D. Lagatouras, G. Vyssoulis, E. Karpanou, N. Nearchou, C. Kouremenou, and P. Skoufas Microalbuminuria Is Determined by Systolic and Pulse Pressure Over a 12-Year Period and Related to Peripheral Artery Disease in Normotensive and Hypertensive Subjects: The Three Areas Study in Greece (TAS-GR) Angiology, May 1, 2006; 57(3): 313 - 320. [Abstract] [PDF]

				R. Agarwal and M. J. Andersen Correlates of Systolic Hypertension in Patients With Chronic Kidney Disease Hypertension, September 1, 2005; 46(3): 514 - 520. [Abstract] [Full Text] [PDF]

				G. C. Shearer, J. W. Newman, B. D. Hammock, and G. A. Kaysen Graded Effects of Proteinuria on HDL Structure in Nephrotic Rats J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1309 - 1319. [Abstract] [Full Text] [PDF]

				M. Ohkita, Y. Wang, N. D. T. Nguyen, Y.-H. Tsai, S. C. Williams, R. C. Wiseman, P. D. Killen, S. Li, M. Yanagisawa, and C. E. Gariepy Extrarenal ETB Plays a Significant Role in Controlling Cardiovascular Responses to High Dietary Sodium in Rats Hypertension, May 1, 2005; 45(5): 940 - 946. [Abstract] [Full Text] [PDF]

				A. Smith, J. Karalliedde, L. De Angelis, D. Goldsmith, and G. Viberti Aortic Pulse Wave Velocity and Albuminuria in Patients with Type 2 Diabetes J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1069 - 1075. [Abstract] [Full Text] [PDF]

				D. J. Brotman, E. Walker, M. S. Lauer, and R. G. O'Brien In Search of Fewer Independent Risk Factors Arch Intern Med, January 24, 2005; 165(2): 138 - 145. [Abstract] [Full Text] [PDF]

				G. F. Mitchell Increased Aortic Stiffness: An Unfavorable Cardiorenal Connection Hypertension, February 1, 2004; 43(2): 151 - 153. [Full Text] [PDF]

				M. E. Safar, G. M London, and G. E. Plante Arterial Stiffness and Kidney Function Hypertension, February 1, 2004; 43(2): 163 - 168. [Abstract] [Full Text] [PDF]

				F. Viazzi, G. Leoncini, D. Parodi, M. Ravera, E. Ratto, S. Vettoretti, C. Tomolillo, M. D. Sette, G. P. Bezante, G. Deferrari, et al. Pulse pressure and subclinical cardiovascular damage in primary hypertension Nephrol. Dial. Transplant., October 1, 2002; 17(10): 1779 - 1785. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pedrinelli, R. Articles by Mariani, M. Search for Related Content PubMed PubMed Citation Articles by Pedrinelli, R. Articles by Mariani, M. Pubmed/NCBI databases Medline Plus Health Information High Blood Pressure Related Collections Other hypertension